STOK ▼ -9.4% - Stoke Therapeutics, Inc. $STOK Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization Stoke Therapeutics fell 9.4% today despite announcing the appointment of Bo Cumbo to its board of directors to bolster commercial expertise as the company progresses zorevunersen toward potential FDA approval. The decline suggests investors may have focused on execution risks or other market factors rather than viewing the board addition as a near-term catalyst for the clinical program's advancement. 23-SEP-2026 04:01 PM ET